ESMO 2024 – Magda Meissner
In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a simple blood draw can transform clinical practice in oncology.
The conversation took place following discussion with Illumina’s Sven Schaffer, focused on molecular profiling of tumours, crucial for optimising cancer treatment in clinical practice, and more specifically circulating tumour DNA (ctDNA) – an innovative approach on the cusp of becoming standard practice in managing patients with advanced cancer.
A significant advancement in precision oncology, Dr Meissner discusses QuicDNA’s research and the role of liquid-based biomarkers for cancer profiling and monitoring, with a view to the future as well.
Tune into the video below, and be sure to catch up on other ESMO 2024 discussions with EVERSANA, Regeneron, Johnson & Johnson, and AbbVie, too.
